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To characterize the promoterome of caudate and putamen regions (striatum), frontal and temporal
cortices, and hippocampi from aged human brains, we used high-throughput cap analysis of gene
expression to proﬁle the transcription start sites and to quantify the differences in gene expression
across the 5 brain regions. We also analyzed the extent to which methylation inﬂuenced the
observed expression proﬁles. We sequenced more than 71 million cap analysis of gene expression
tags corresponding to 70,202 promoter regions and 16,888 genes. More than 7000 transcripts were
differentially expressed, mainly because of differential alternative promoter usage. Unexpectedly,
7% of differentially expressed genes were neurodevelopmental transcription factors. Functional
pathway analysis on the differentially expressed genes revealed an overrepresentation of several
signaling pathways (e.g., ﬁbroblast growth factor and wnt signaling) in hippocampus and striatum.
We also found that although 73% of methylation signals mapped within genes, the inﬂuence of
methylation on the expression proﬁle was small. Our study underscores alternative promoter
usage as an important mechanism for determining the regional differences in gene expression at
old age.
 2013 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
The brain is themost complex organ of the human body, and this
complexity is a major landmark of human evolution (Konopka and
Geschwind, 2010). The brain can be divided into different functional
and anatomic regions that are established during development and
maintained throughout life. The mechanisms that regulate normal
brain function and differentiation are controlled by both genetic
(Johnson et al., 2009) and epigenetic factors (Miller and Sweatt,
2007), and alterations in these mechanisms can lead to neu-
rodegenerative diseases (Abdolmaleky et al., 2005). There
have been tremendous advances in our understanding of thecal Genetics, VU University
msterdam, The Netherlands.
sevier OA license.molecular mechanisms involved in brain function, and the regional
differences in these functions are beginning to be understood
(Khaitovich et al., 2004; Roth et al., 2006). Less is known about the
genetic mechanisms that are responsible for establishing and
maintaining these differences throughout development, adulthood,
and aging. Insights into these mechanisms are required to under-
stand the differential susceptibility of distinct brain regions to
neuronal insults (Double et al., 2010). For example, the genes for
which mutations have been characterized in Alzheimer’s disease
(AD) (Joachim et al., 1989; Shen et al., 1997) and Parkinson’s disease
(PD) (Bandopadhyay et al., 2004) are often ubiquitously expressed
whereas the observed pathology is restricted to speciﬁc brain
regions and speciﬁc cell types (Double et al., 2010). Dissection of the
molecular basis of this selective vulnerability will be pivotal to our
understanding of disease pathogenesis and the development of
speciﬁc therapies.
Much of our current insight into the molecular basis of
brain function results from detailed studies of single genes or
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genetic mutations (Hardy and Selkoe, 2002). However, unbiased
approaches, where large numbers of genes are assessed simulta-
neously, are expected to be more powerful to dissect the genetic
mechanisms controlling brain function. Large-scale analysis of gene
expression in brain was pioneered by microarray experiments
(Khaitovich et al., 2004). In recent years, high-throughput
sequence-based technologies have been developed to analyze the
mammalian transcriptome in more detail and at greater depth
(Sandelin et al., 2007). These technologies have been decisive to
uncover a complex picture of the mammalian transcriptome
(Carninci et al., 2005) and to identify new mechanisms of gene
regulation and control of gene expression in brain (Kang et al., 2011;
Tollervey et al., 2011). Among sequence-based technologies, tag-
based approaches such as cap analysis of gene expression (CAGE)
have been used to comprehensively proﬁle the transcription start
sites (TSSs) and the promoter regions (Takahashi et al., 2012). CAGE
is a cap-trappingebased method that proﬁles 50 capped transcripts
of both coding and noncoding RNA classes and has been pivotal in
the discovery of alternatively regulated TSSs and novel regulatory
elements (Carninci et al., 2006; Valen et al., 2009).
To understand how different promoters and control elements of
genes establish and maintain region-speciﬁc expression patterns,
we used CAGE in combination with massive parallel sequencing to
proﬁle TSSs of brain regions in 7 aged healthy individuals, at
a genome-wide scale. We selected 5 samples of caudate nuclei,
putamen, frontal and temporal cortices, and hippocampus, which
are speciﬁcally vulnerable in the most prevalent neurodegenerative
disorders (Double et al., 1996). First, we characterized the tran-
scriptome of aged human brain and evaluated the extent of alter-
native promoter usage. Second, we quantiﬁed differences in gene
expression and promoter usage across 5 brain regions. Finally, we
analyzed the extent to which methylation inﬂuenced the observed
expression proﬁles.Table 1
Description of the tag counts per region/sample
Individual Region Batcha RIN Tag counts
1 Caudate 1 7.6 1,988,794
1 Frontal 1 7 3,453,682
1 Hippocampus 1 6.5 2,022,640
1 Putamen 1 7.7 3,814,753
1 Temporal 1 6.3 4,333,255
2 Hippocampus 1 6.5 1,682,943
2 Caudate 2 7.2 1,663,688
2 Frontal 2 6.9 1,745,155
2 Putamen 2 6.5 1,216,441
2 Temporal 2 6.8 936,396
3 Frontal 2 7.1 2,111,277
3 Hippocampus 2 8.8 1,785,386
3 Temporal 2 6.8 1,103,935
4 Temporal 2 5.9 1,199,974
4 Frontal 2 6.5 2,035,347
4 Hippocampus 2 6.4 1,251,589
4 Putamen 2 6.5 2,541,166
5 Caudate 1 7.9 3,096,524
5 Putamen 1 6.6 4,029,122
6 Caudate 1 7.4 3,587,220
6 Putamen 1 6.3 2,085,385
7 Caudate 1 6.8 4,875,578
7 Frontal 2 6.2 2,324,932
7 Hippocampus 2 6.2 3,158,604
7 Temporal 2 6.2 1,104,711
Details on the quality control and ﬁnal counts used for the analysis are presented in Sup
Key: RIN, RNA integrity number.
a Refers to 2 main batch effects corresponding to different period of times in which th
b Refers to the total tag counts after removal of sequencing artifacts.
c Refers to the tag counts that map to single positions in the genome unique regions.
d Refers to proportion of tags that mapped to less than 10 positions.
e Refers to the proportion of tags that mapped to ribosomal DNA.2. Methods
2.1. Brain specimens
The postmortem brain tissues were obtained from the
Netherlands Brain Bank (Amsterdam, The Netherlands). The donors
were aged subjects (age range: 70e91 years) without clinical signs
of neurodegenerative or psychiatric disorders. All brains were
neuropathologically evaluated by an experienced neuropathologist
and classiﬁed for neuroﬁbrillary tangles stage 0eVI (Alafuzoff et al.,
2008), amyloid-beta plaques score 0eC, and Braak a-synuclein
stage 0eVI using the staging protocols of Brain Net Europe and
Braak (Alafuzoff et al., 2009a, 2009b; Braak et al., 2006). The
dissection of the caudate, putamen, hippocampus, middle frontal
gyrus (F2), and middle temporal gyrus regions was performed from
snap frozen human brain sections. Tissue was stored at80 C until
further processing. Pathologic examination of the brain specimens
showed changes consistent with the age of the individuals. The age
at death, cause of death, and postmortem delay until dissection are
provided in Supplementary Table 1.
2.2. CAGE library preparation
Total RNA was extracted and puriﬁed from tissues using the
Trizol tissue kit according to the instructions provided by the
manufacturer (Invitrogen). RNA quality per library was assessed
using the RNA integrity number with the Agilent Total RNA Nano kit
(Table 1). The standard CAGE protocol (Kodzius et al., 2006) was
adapted for sequencing on an Illumina platform. A thorough
description of the protocol to prepare CAGE libraries and to
sequence CAGE tags is presented in Takahashi et al. (2012). Brieﬂy,
complementary DNA (cDNA) was synthesized from total RNA
using random primers, and this process was carried out at high
temperature in the presence of trehalose and sorbitol to extendb Unique countsc Mapping rated Ribosome mappinge
935,084 0.856 0.062
1,531,751 0.866 0.049
979,162 0.811 0.09
1,627,659 0.826 0.069
1,937,270 0.822 0.07
310,481 0.843 0.072
362,468 0.724 0.088
801,757 0.822 0.04
274,776 0.702 0.113
259,968 0.748 0.103
505,207 0.779 0.068
413,336 0.816 0.041
255,621 0.84 0.041
356,840 0.71 0.127
472,327 0.739 0.107
335,644 0.731 0.109
516,842 0.73 0.121
1,144,105 0.875 0.059
1,541,543 0.834 0.082
1,296,765 0.875 0.053
795,569 0.868 0.072
1,625,317 0.862 0.062
407,993 0.731 0.111
597,669 0.775 0.033
241,508 0.699 0.157
plementary data. Individual, region and batch id are presented in bold.
e cap analysis of gene expression libraries were prepared (Supplementary data).
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(UTRs). The 50 ends of messenger RNA within RNA-DNA hybrids
were selected by the cap-trapper method (Kodzius et al., 2006) and
ligated to a linker so that an EcoP15I recognition site was placed
adjacent to the start of the cDNA, corresponding to the 50 end of the
original messenger RNA. This linker was used to prime second-
strand cDNA synthesis. Subsequent EcoP15I digestion released the
25- to 27-base pair (bp) CAGE tags. After ligation of a second linker,
CAGE tags were polymerase chain reaction ampliﬁed, puriﬁed, and
sequenced on the Illumina Genome Analyzer GLXII platform
(Takahashi et al., 2012). The data have been submitted to the Gene
Expression Omnibus (GEO) public repository (GSE43472).
2.3. DNA methylation microarrays
DNA isolation and puriﬁcation to detect methylation was
carried out following standard protocols (Supplementary data,
Methods). Genome-wide ampliﬁed input and output samples
were sent to Roche NimbleGen where they were hybridized to
DNA Methylation 2.1 Million Deluxe Promoter Arrays. The arrays
have a mean probe spacing of 99 bp and median probe spacing of
100 bp. Each array has more than 2.1million probes distributed in
the following manner (1) promoter regions from 7250 bases
upstream of each TSS to 3250 bases downstream; (2) micro RNA
(miRNA) genes, starting from 15 kbp upstream of the mature gene
product to its 30 end; (3) CpG islands; and (4) ENCODE regions.
Probes were chosen from the hg18 tiling database. Therefore, the
probes targeted mainly annotated promoter regions and CpG
islands.
2.4. Bioinformatics and statistical analysis of CAGE data
Primary quality control analysis included the removal of linker
and barcode sequences as well as other sequencing artifacts to
obtain raw CAGE tags of approximately 27 bps. Next, raw CAGE tags
were mapped to the human genome (hg18 build) using Nexalign
(T. Lassmann, http://genome.gsc.riken.jp/osc/english/dataresource/)
allowing for 1 mismatch and 1 indel. The above steps were carried
out with scripts and software (see Lassmann et al., 2009) deve-
loped at the RIKEN. Following previous approaches to analyze
promoter activity based on CAGE data, we grouped raw CAGE tags
into CAGE clusters using a clustering pipeline from Omics Science
Center bioinformatics at the RIKEN (De Hoon et al., 2010). In brief,
the CAGE tags that mapped to the same position in the human
genome and were on the same strand were considered CAGE
Transcription Start Sites (CTSSs) (level 1 [L1]). For tags that mapped
to multiple positions in the genome, a rescuing approach was
applied (Faulkner et al., 2008). L1 CAGE tags were clustered into
level 2 tag clusters (L2 TCs) if they overlapped within 20 bps and
were on the same strand. L2 TCswere grouped into level 3 (L3) TCs if
they overlapped within a region of 400 bps and were on the same
strand. For clarity, a CTSS marks the ﬁrst nucleotide that is tran-
scribed into RNA and is considered a putative TSS, whereas a L3 TC
encompasses the region that is shared between proximal TSSs
(Supplementary data, Methods) (Sandelin et al., 2007). After clus-
tering approach, we obtained 6,735,699 CTSSs (L1 clusters). To
increase the probability of capturing genuine promoter regions, we
only selected L3 TCs that were present in at least 2 CAGE libraries
and with a minimum count of 5 tags per million (TPM) (De Hoon
et al., 2010) in at least 1 library; for example, only CTSS present at
5 TPM in one library and1 TPM in another were included. For all
downstream analysis, we used the L3 TCs. Unless stated otherwise,
TCs refer to the L3 TCs.
Next, we annotated TCs to human genes by mapping the
coordinates of the TCs to all available transcripts from GENCODEversion 3d. To do this, we downloaded all GENCODE transcripts
from the UCSC genome browser (hg18 build; University of Cal-
ifornia, Santa Cruz, CA [UCSC]) at different levels of validation
(http://genome.ucsc.edu/cgi-bin/hgTables). Custom Perl scripts and
BEDTools (Quinlan and Hall, 2010) were used to map the coordi-
nates of the TCs to genomic regions corresponding to speciﬁc
transcriptional units (Carninci et al., 2006). TCs that did not map to
a speciﬁc gene were considered intergenic. Further, we divided the
TCs into mutually exclusive classes according to the gene region
they mapped to. TCs that mapped to a 50 UTR or 300/þ100 bps of
a known TSS (core promoter region) were labeled as canonical. The
remaining noncanonical TCs were labeled as 50 UTR antisense, 30
UTR, 30 UTR antisense, intronic, exonic, intronic antisense, and
exonic antisense.
We classiﬁed the genes towhich the TCsmapped to according to
the following Biotypes: protein-coding gene (if it had an open
reading frame), long noncoding RNA (lncRNA), miRNA, pseudogene,
processed transcript (no open reading frame, but transcribed and
not classiﬁed into any other category), and other ncRNAs using the
deﬁnitions from GENCODE (Harrow et al., 2006) (http://www.
gencodegenes.org/gencode_biotypes.html).
2.4.1. Differential gene expression and promoter usage derived from
CAGE data across 5 brain regions
To obtain an overview of the expression (count) proﬁle of the
CAGE libraries, we ﬁrst tested for differential expression across
brain regions and subsequently identiﬁed patterns of differences
between these regions by means of hierarchical clustering. We
focused on autosomal TCs with a minimum of 9 tag counts per TC
because this is the minimum number of counts needed to get
reliable estimate of expression (Robinson et al., 2010). We built
a model that takes into account both biological and technical
variations, as we found that tag expression was subject to batch
effects (Supplementary data, Results). The model assumes that
CAGE tag counts (yij) follow a negative binomial distribution, which
is standard for modeling read/tag counts. It also includes brain
group (5 levels corresponding to 5 regions), batch (2 levels corre-
sponding to 2 main batches [Supplementary data, Results]), and
individual (7 levels corresponding to 7 individuals) as covariates.
Details of the mathematical and statistical procedure are presented
in Supplementary data, Methods.
To identify differentially expressed TCs (DETC) showing similar
differences among (a subset of) groups, we carried out hierarchical
clustering (with Euclidean distance) based on the coefﬁcients of
brain regions, which are lower than 3 in absolute value. This was
carried out with the R function hclust from package stats (with
default agglomeration method). We chose the partition that
maximized the average silhouette index width.
Functional enrichment analysis was subsequently done on
clusters (modules) of DETCs using the PANTHER version 7.0 data-
base (Supplementary data, Methods). All further functional
pathway analyses were carried out using this database.
2.5. Bioinformatics and statistical analysis of methylation data
The log2 ratio of the probe intensity in the experimental sample
against control DNA was determined. The log2 methylation signals
were converted into methylation peaks (MPs) using the NimbleGen
software (Roche) with default parameters (Supplementary data,
Methods). Further, we removed MPs that mapped to X and Y
chromosomes as well as those that overlapped with centromeres,
telomeres, and segmental duplications. MPs overlapping with
regions in which more than 1 segment was detected for a single
sample were also removed. Next, we selected consensus MPs that
were shared in a minimum of 2 samples. For this, we used the plink
Fig. 1. Annotation of level 3 (L3) cap analysis of gene expression (CAGE) tag clusters
(TCs) to human genes. (a) Barplot showing the percentage of TCs (y-axis) that map to
different gene regions: promoters, 50 untranslated regions (UTRs), 30 UTRs, antisense,
introns, exons, antisense introns, antisense exons, antisense 50 UTR, antisense 30 UTR,
and outside genes (intergenic). Promoter regions were deﬁned as 300/100 base pairs
relative to the 50 UTR. We deﬁned canonical TCs those that mapped to promoters or 50
UTRs. The TCs that mapped to other regions were classiﬁed as noncanonical. The
proportion of canonical TCs represents one-third of all TCs we identiﬁed. (b) Distri-
bution of biotype classes for genes with canonical L3 CAGE TCs. Pie chart showing the
percentage of genes with at least 1 canonical TC classiﬁed by biotype class: protein-
coding genes (gene with open reading frame), long noncoding RNAs (lncRNAS),
pseudogenes, micro RNAs (miRNA), small nucleolar RNAs (snoRNA), and processed
transcripts (no open reading frame but transcribed and not classiﬁed into any other
category).
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methylated “segments” with the command: plink ﬁle –segment-
group. Next, we used BEDTools (Quinlan and Hall, 2010) to map the
MPs to annotated human genes (hg18) using GENCODE version 3d
at different levels of annotation. We also mapped the MPs to CpG
islands downloaded from UCSC browser (Fujita et al., 2011). Details
of the experimental protocol and the downstream analysis are
presented in Supplementary data.
2.5.1. Differential methylation analysis
We modeled the log2 ratios of the probe intensities taking both
biological and technical variations into account and assuming that
the ratios followed a normal distribution. Brain group (here we
used the caudate as reference group), batch, and individual factors
were covariates. We ﬁtted 2 models per methylation probe: a full
model, which included all 3 covariates and a null model where the
factor brain group was discarded. We tested for differences in the
models using a one-way analysis of variance, implemented in R
version 13, and adjusted for multiple testing using the Bonferroni
correction. Differentially methylated peaks (DMPs) were deﬁned as
differentially methylated probes occurring at a minimum overlap of
300 bps (R script provided by K. Lo at Roche, k.lo@roche.com).
2.5.2. Correlation between methylation signals and expression
First, we calculated the average methylation for every MP,
adjusting for both biological and technical variations as mentioned
previously. Next, we overlapped the genomic coordinates of the
MPs with the genomic coordinates of the TCs (1500/þ500) using
BEDTools (Quinlan and Hall, 2010) and estimated the Spearman
correlation between the averagemean intensity of methylation and
the average expression of the overlapping TCs (geometric mean).
To test whether the expression of individual TCs were affected
by methylation, we used the same statistical framework that we
used to identify DETCs but included the methylation covariate as
the variable of interest. Brieﬂy, for each TC, we ﬁtted 2models. A full
model with brain group, batch, and methylation as covariates, and
a null model where methylationwas removed. Because of the small
number of MPs overlapping TCs, we could not ﬁt the individual
covariate. Signiﬁcant differences were calculated as above.
3. Results
Supplementary Fig. 1 shows a schema of the main steps of
experimental procedure and the data analysis we carried out in this
study. We prepared 25 CAGE libraries from total RNA isolated from
the caudate nuclei, putamen, frontal and temporal lobes, and
hippocampus from the 7 donors. In total, we sequenced 72 million
CAGE tags (1e2 million per library approximately) in 5 sequencing
rounds. Table 1 summarizes the tag count and mapping rate per
library after quality control (Supplementary data, methods). The
ﬁnal set of L3 TCs that were available for analysis numbered 70,202.
3.1. Features of brain transcriptome of aged individuals derived
from CAGE
We mapped the TCs to 16,888 human genes from the GENCODE
database (Raney et al., 2011). Fig.1a shows that 31.2% of TCsmapped
to the 50 UTR or promoter regions of previously annotated tran-
scripts (canonical TCs), whereas the remaining 68.9% mapped to
other regions including introns, exons, and 30 UTRs (noncanonical
TCs). In addition, 13.6% of TCs did not map to any known transcript
and were considered intergenic. Of these TCs, 559 (6%) mapped to
lncRNAs (Jia et al., 2010) (Supplementary Table 2). Although
canonical TCs represented less than one-third of all TCs (Fig. 1a),
their expression was high and accounted for most of the overall TCexpression. In contrast, the expression of most noncanonical TCs
was low (Supplementary Fig. 2).
Of all the expressed genes, 14,479 (87%) had canonical TCs
(Supplementary data, Data set 1). As shown in Fig. 1b, 90% of these
genes encode proteins. The remaining 10% consist of ncRNA, of
which annotated pseudogenes account for 33%. We compared the
list of genes that were expressed in our data set with those from
RNASeq data from brain and other tissues (Ramskold et al., 2009).
We found an overlap of 77% (Supplementary Fig. 3). Genes
expressed in brain according to Ramskold et al. (2009) that were
not present in our CAGE data set included both mitochondrial (e.g.,
MT-ATP6, MT-ND3, and MT-CO2) and ribosomal genes. In contrast,
Fig. 2. Distribution of the number of alternative tag clusters (ATCs) per gene. (a) The
empirical cumulative distribution (y-axis) of the number of ATCs per gene (x-axis) and
(b) number of ATCs per bin category. The number of genes with 2 or more ATCs is
shown at the top of every bin category.
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(24% more compared with RNASeq, Supplementary Fig. 3b), with
a particular enrichment for pseudogenes and lncRNAs.
We looked at the expression proﬁle of 1909 highly expressed
genes with canonical TCs (90th percentile of the log geometric
mean of expression distribution; Supplementary Table 3) in more
detail. This group included genes involved in brain aging (e.g.,
GPAFP, SPARCL1, and B2M, Starkey et al., 2012), calcium homeostasis
(CALM1e3), neurodegeneration (CLU and PICALM, Mengel-From
et al., 2011), and oxidative stress (e.g., PTGD2, CA11 and SOD1,
Pareek et al., 2011). We carried out functional enrichment analysis
using PANTHER version 7.0 (Mi et al., 2009; Thomas et al., 2003) on
the group of highly expressed genes. Although many genes could
not be classiﬁed, the most signiﬁcant molecular pathways identi-
ﬁed included the ubiquitin-proteasome pathway, synaptic trans-
mission pathway, Huntington’s disease, and PD (Supplementary
Fig. 4). The overrepresentation of the PD pathway was mediated
through genes encoding components of the ubiquitin-proteasome
pathway (e.g., PSMA1 and PSMA2), heat shock proteins (e.g.,
HSPA2 and HSPA5), cell cycle components (e.g., SEPT2, SEPT4, and
SEPT5), and synaptic genes (e.g., SNCA) among others. This shows
that genes, for which mutations and/or variants that have been
associated with PD, are components of cellular pathways that are
highly expressed in the cortical and subcortical brain regions.
3.2. Extent of alternative promoter usage in brain transcriptome
We deﬁned alternative TCs (ATCs) as those that mapped to the
same gene but were separated by a distance of >300 bp. TCs that
were unique for a single genewere deﬁned as “dominant TC” (DTC).
Compared with DTCs, ATCs were mostly noncanonical and at least
34% of them mapped to introns.
In our data, 60% of genes (10,205 of 16,888 expressed genes)
used ATCs (mean 5, range of 2e356, Fig. 2). Most genes with ATC
had at least 1 canonical TC. We noted that the number of ATC per
genewas above 10 for 10% of the genes (Fig. 2). Because some of the
genes were quite large, we used linear regression to model the
number of ATC per gene (for genes with at least 16 ATCs- 5% of the
genes with large number of ATCs) against gene size. We found
a correlation of about 0.3 (R ¼ 0.28, p value <2.2e16). This shows
that gene length does not account to a large extent for the excess of
ATC in genes. Outlier genes included KCNIP4, PCDH9, CADM2, BAI3,
NRG3, LSAMP, NRXN1, LRRTM4, and FGF14, each with at least 100
ATCs. Functional enrichment analysis on genes with more than 16
ATCs (469 genes) showed an overrepresentation of glutamate
receptor signaling and synaptic plasticity although most of the
genes remained unclassiﬁed.
3.3. Regional differences in TC expression across the 5 brain regions
To identify signatures of gene expression across different brain
regions, we sought CAGE clusters that were differentially expressed
in one or more of the brain regions. We modeled the expression of
the TCs using the number of counts and tested for signiﬁcant
differences in expression because of “regional effects” (see Section
2).We identiﬁed 7412 DETCs. Of these, 6037were ATC of geneswith
a main canonical promoter. We identify neither any major differ-
ences in biotype between the differentially and nondifferentially
expressed groups nor an excess of antisense TCs.
Fig. 3 presents the results of the hierarchical clustering for the
7412 DETCs. We identiﬁed 3 main branches: one connecting the
striatal regions (caudate and putamen), one connecting the cortical
regions (frontal and temporal), and a third that separated the
hippocampal region from the other 2 groups. Fig. 3 also shows that
the TCs were grouped into different clusters. We separated theDETCs into nonoverlapping modules (groups of TC that were
differentially expressed in one or more regions) and identiﬁed
29 modules (Table 2). The largest module (M13) was characterized
by small differences in expression across regions, and no regionwas
clearly separated from the rest (Supplementary Fig. 5a). The other
modules were characterized by more obvious differences in the
average counts in 1 or 2 brain regions relative to the others
(Supplementary Fig. 5bed). These included M18 (lower expression
in striatum vs. cortical regions and hippocampus), M4 (decreased
expression in the caudate nucleus vs. the rest), M27 (lower
expression in hippocampus), and M2 (increased expression in the
cortex).
We evaluated whether speciﬁc signaling, metabolic, and disease
pathways were enriched in the differentially expressed modules
with at least 100 TCs. We used all the genes that were expressed in
our data and that could be annotated in PANTHER version 7.0 as
a reference set (Supplementary Table 4a shows the pathways that
were signiﬁcantly enriched in the reference group). Compared with
the reference group, few pathways were enriched in the set of
differentially expressed modules (Supplementary Fig. 6). The
most signiﬁcant pathway was the ﬁbroblast growth factor (FGF)
signaling pathway in M27 (lower expression in hippocampus) (p
value <0.0005). Several genes from the FGF pathway were differ-
entially expressed, including FGF12, FGF14, RASA1, MAPK6,MAPK10,
PPP2R2B, and PPA2. All these genes had a main canonical TC that
Fig. 3. Unsupervised clustering of differentially expressed tag clusters (DETC). The
graph depicts the unsupervised clustering of the b coefﬁcients of the factor “region”
derived from the statistical analysis of differences in expression because of regional
effects (see Section 2). The dendrogram at the top shows that basal ganglia cluster
together and that frontal and temporal cortices cluster together. The dendrogram at
the left of the graph was used to split the DETCs into functional modules (see
Results).
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reduced expression in hippocampus. Other signiﬁcant pathways
(p value <0.005) included platelet-derived growth factor signaling
in M6 (lower expression in caudate compared with all other reg-
ions); synaptic trafﬁcking inM2 (higher expression in cortex than in
striatum and hippocampus) and M27 (lower expression in hippo-
campus); and glutamate receptor type I (metabotropic glutamate
receptor group I [mGluRI]),Wnt signaling, and Huntington’s disease
pathways in M18 (lower expression in striatum compared with
cortex and hippocampus). These signiﬁcant pathways mediate
many cell functions including proliferation, differentiation, and
survival (Goldbeter and Pourquié, 2008; Moon et al., 2004; Peng
et al., 2010). A list of enriched pathways per module and genes
with TC in each of the pathways is presented in Supplementary
Tables 4a and b, respectively.3.4. Unexpected expression of neurodevelopmental transcription
factors in aged brain
To investigate whether differential promoter usage across brain
regions can be explained by differences in the manner in which
they are regulated, we searched for transcription factors (TFs) that
were differentially expressed across the 5 regions. We mapped all
DETCs to a manually curated list of TFs (Vaquerizas et al., 2009). We
identiﬁed 519 DETCs that mapped to 320 TF genes, although only
20% mapped to the promoter or 50 UTR region (Supplementary
Table 5). The DETF with the highest expression included those
involved in neuronal postmitotic differentiation and laminar
integrity in the cortex (e.g., TBR1, Bedogni et al., 2010, NR2F1, Naka
et al., 2008, NEUROD1, NEUROD2, BHLHE22, and MEF2C) and
neuronal plasticity (e.g., NR4A1) (Table 3 presents the top 20 most
highly expressed TF per module). Most of the DETCs that mapped to
TF were ATCs. One exception was a DTC that mapped to the
promoter region of the KLF5 gene and was differentially expressed
in M27. KLF5 has been shown to regulate survival and apoptosisthrough the regulation of MAPK kinase pathway. Other TFs that are
module speciﬁc are presented in Supplementary Table 5.
To identify speciﬁc TFs that were coexpressedwith (and possibly
regulate) the DETCs, we screened proximal (300/þ100 bp) and
distal (1500/þ500 bp) promoter sequences of all TCs for tran-
scriptional factor binding sites (TFBS) using remote dependency
models (see Supplementary data, Methods). Overall, we identiﬁed 3
classes of TFBS that were signiﬁcantly overrepresented in the
promoter regions of the DETC, namely, BPTF (FAC1), the TBX family,
and CUX1 (CDP). These TFs stand out as regulators during neuro-
development including dendritogenesis (CUX1) (Cubelos et al.,
2010), cortical formation (Tbr1-TBX) (Bedogni et al., 2010), and
neurite outgrowth (BPTF) (Rhodes et al., 2003). On the other hand,
we found that 15 classes of TFBS were signiﬁcantly underrepre-
sented including E2F, EGR (KROX), the Sp family (Sp1 and Sp3), Elk1,
ATF6, CREB1, andMYC, and KLF5. These TFs are known to be involved
in apoptosis (E2F and KLF5) and synaptic plasticity (EGR1-2, CREB,
KLF5, and Elk).
We also screened every module separately. We identiﬁed
signiﬁcant over/under-representation of TFBS in 19 out of the 29
modules (Supplementary Table 6a and b). The TBX binding site was
overrepresented in most of the modules, whereas the BPTF binding
site was signiﬁcantly overrepresented in M13 and M27. Other TFBS
were overrepresented although they did not reach statistical
signiﬁcance (Supplementary Table 6a and b).
3.5. The extent of methylation in the brain transcriptome of aged
individuals
DNA methylation at CpG nucleotides is another crucial mecha-
nism for the regulation of gene expression (Jones, 2012). To inves-
tigate to what extent the patterns of expression in our data
correlated with methylation, we analyzed methylation signatures
in all 25 samples. After quality control and ﬁltering, we obtained
551,178 MPs distributed and 95,715 of these were shared by at least
2 samples (of the 25 samples) and were used for downstream
methylation analysis. We ﬁrst assessed how many annotated genes
from GENCODE were methylated and found that 73% of all meth-
ylation signals mapped within genes (Fig. 4), 43% to introns, 27% to
exons, and 25% to promoter regions. We also looked at the
proportion of methylation signals that occurred within CpG islands.
We found that only 6% of methylated regions mapped within CpG
islands. Of the promoters that mapped within CpG islands (45% of
total), only 38% were methylated. Our data show that most of the
methylated genomic regions occur in gene bodies and outside CpG
islands (the list of MPs we used for the analysis is available on
request).
3.5.1. Regional differences in methylation across the 5 brain regions
To identify DMP, speciﬁc for speciﬁc brain regions, we modeled
the MPs using a linear model for regional effects, adjusting for both
individual and possible methylation batch effects. Using this
approach, we identiﬁed 13,423 DMPs, and of these 75.9% were
mapped within gene bodies. Genes that were differentially meth-
ylated included NRXN1, ITPR1, MADD, CNTNAP1, SRR, GABBR1,
INPP5A, HTR1D, DLGAP1, and TIAM2, which have been previously
shown as methylated (Iwamoto et al., 2011) and that we found
differentially methylated in frontal cortex.
We also compared the list of DMPs with MPs derived from
Davies et al. (2012), where differences in methylation across several
brain areas (mainly cortex and cerebellum) and blood were re-
ported. We found that at least 39% of the DMPs overlapped with
these from Davies et al. (2012). Moreover, several genes that we
found differentially methylated showed also differences in meth-
ylation between cerebellum and cortex (e.g., AACS, ADCY5, EPHB4,
Table 2
Number of DE clusters identiﬁed for the DETCs
Module 
id No. TCs Caudate Putamen Hippocampus Frontal Temporal
Proportion 
of all DE TC
13 3190 0.43
18 1063 0.143
6 683 0.092
27 295 0.04
2 273 0.037
20 256 0.035
23 170 0.023
4 163 0.022
19 164 0.022
10 155 0.021
16 119 0.016
8 116 0.016
11 107 0.014
3 107 0.014
9 91 0.012
7 74 0.01
22 51 0.007
1 41 0.006
25 45 0.006
17 43 0.006
5 38 0.005
12 39 0.005
26 38 0.005
15 28 0.004
28 12 0.002
21 18 0.002
29 12 0.002
24 11 0.001
14 10 0.001
Total 7412
Dark gray represents higher expression relative to other regions. Light gray represents lower expression relative to other regions. Black represents similar expression proﬁle for
all regions.
Key: DETCs, differentially expressed tag clusters.
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PCDH9, PDE4D, and PPP2R2B). This analysis shows that as much as
39% of methylated regions in brain (as identiﬁed by 2 different
approaches) exhibit differences in their methylation proﬁle in the
brain regions we analyzed. The list of DMPs that we identiﬁed and
that overlapped with MPs from Davies et al. (2012) is presented in
Supplementary data, Data set 2).
3.5.2. Correlation between MPs and expression
To analyze the correlation between expression and methylation
in our data, we ﬁrst overlapped the genomic coordinates of both
data sets considering promoter regions from 1500 to þ500 bp
relative to the most highly expressed TSS. We found that only 9%of all TCs overlapped with at least 1 MP. Overall, there was
no signiﬁcant correlation between methylation and expression
(Spearman correlation: r ¼ 0.05), most likely because of the
large variation in the methylation of TCs with very low counts
(Supplementary Fig. 8). We also analyzed the correlation between
methylation and expression for protein-coding genes and non-
coding genes separately (the number of ncRNA genes that over-
lapped with the MPs was too small to be analyzed independently)
and did not observe any difference in their correlation coefﬁcients
(Spearman correlation of 0.06 and 0.07 for ncRNAs and protein-
coding genes, respectively). Therefore, we tested for signiﬁcant
differences in expression because of “methylation effects” at indi-
vidual TCs adjusting the expression for brain region and batch
Table 3
List of 20 most highly differentially expressed TF
TC ID Start End TF Module Mean (geometric)
L3_chr2_þ_161981068 161980893 161981527 TBR1 (tbx family) 13 28.718
L3_chr5_þ_92946017 92945793 92946068 NR2F1(COUP-tf1) 13 6.658
L3_chr12_þ_50731491 50731420 50731653 NR4A1 13 6.035
L3_chr7_þ_39092007 39091721 39092121 POU6F2 13 5.520
L3_chr8_þ_65655474 65655301 65655790 BHLHE22 13 5.035
L3_chr19__41561943 41561901 41561975 ZFP14 13 4.983
L3_chr5__88155431 88155327 88155565 MEF2C 13 4.965
L3_chr1__925340 925274 925452 HES4 13 4.738
L3_chr2__182253487 182253446 182253729 NEUROD1 13 4.271
L3_chr2__242205564 242205419 242205632 THAP4 13 3.994
L3_chr17__35017699 35017598 35017742 NEUROD2 13 3.946
L3_chr3_þ_69871321 69871264 69871369 MITF 13 3.937
L3_chr13_þ_72531139 72531098 72531259 KLF5 27 3.847
L3_chr4_þ_146623601 146623337 146623645 SMAD1 13 3.750
L3_chr9__37455447 37455266 37455461 ZBTB5 13 3.745
L3_chr13__73606569 73606482 73606578 KLF12 13 3.587
L3_chr1_þ_13977672 13977542 13977772 PRDM2 13 3.446
L3_chr19_þ_60846825 60846530 60846828 ZNF581 13 3.399
L3_chr7_þ_38984037 38983927 38984054 POU6F2 13 3.380
L3_chr2_þ_45022343 45022302 45022747 SIX3 3 3.366
Key: TC, tag cluster; TF, transcription factor.
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present in at least 5 libraries. After correcting for multiple testing,
we identiﬁed 312 TCs (5%) with differences in expression because of
methylation effects. Of these, 34 TCs also exhibited differences in
expression per region. Therefore, the differential expression
because of regional effects we observed earlier was not driven by
differences in methylation to a large extent. Genes with differences
in expression per region because of methylation status included
CDK10, NRN1, PYCARD, TIMP3, and UCP2. For these genes, promoter
methylation has previously shown to regulate expression (Gloss
et al., 2011; Konishi et al., 2011).
3.6. Effects of methylation on TF expression and TFBS
We compared the methylation status of differentially and non-
DETFs. We did not identify any signiﬁcant difference in the
proportion of methylated TFs between the 2 groups (7% and 10% for
differentially and non-DETFs, respectively). However, there wasFig. 4. Percentage of methylation peaks mapping to diffa signiﬁcantly higher proportion of MPs mapping to the 30 UTR
regions in the DETFs (50% vs.15%, Fisher p¼ 0.0001), whereas in the
group of non-DETFs, most of the MPs mapped to the canonical
promoter region (11% vs. 42%, Fisher p ¼ 0.0058).
We also analyzed whether methylation could affect the
expression of TCs by binding to their TFBS, presumably by modi-
fying the spatial structure of binding sites (Choy et al., 2010). We
screened the TFBS identiﬁed previously for overlaps with differ-
entially MPs and found 304 TFBS in such locations (details of the
statistical analysis are provided in Supplementary data, Methods).
Out of all these TFBS, we only selected those, which overlap with
differentially MPs showing a negative correlation between
expression and methylation. Because of low number of high
conﬁdent TFBS predictions made by RDM, we only identiﬁed a few
TFs having several binding sites in such locations, namely, E2F
group, Sp1:Sp3 complex, AP2alphaA, FAC1, and NHLH1 (for details,
see Supplementary data, Methods and Table 7). This coincided
with the underrepresentation of predicted TFBS for certain TFBSerent gene regions, within and outside CpG islands.
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Table 6a and b), suggesting that the corresponding TFs even being
nondifferentially expressed may be involved in regulation of
differential expression.
4. Discussion
In this study, we used CAGE in combination with massive
parallel sequencing to proﬁle transcription initiation across 5
different brain regions of aged, nondemented individuals and
evaluated the extent of region speciﬁcity in alternative promoter
usage and expression. At a sequencing depth of 1e2 million CAGE
tags per library, we found that 40% of all GENCODE genes were
expressed in brain. This estimate is probably conservative because it
has been shown that deeper sequencing is needed to identify rare
functional transcripts (Mercer et al., 2011). In addition, we anno-
tated 6% of intergenic TCs to 559 lncRNAs that had previously only
been predicted in silico.
We found that 77% of the genes with canonical TCs in our data
set overlap with another brain transcriptome data set derived from
RNA-Seq methodology (Ramskold et al., 2009). Comparing the
2 data sets reveals that CAGE detects more ncRNA transcripts (e.g.,
lncRNAs and pseudogenes) whereas the proportion of protein-
coding genes was higher with RNA-Seq. These differences could
be the result of differences in sequencing depth or due to marked
differences in the experimental design of both approaches. Indeed,
although CAGE and RNA-Seq can be used to quantify the amount of
gene expression and that there is a high correlation of gene
expression between these 2 approaches (0.57, see Dong et al., 2012),
RNA-Seq libraries are commonly enriched for poly Aþ transcripts
(Mortazavi et al., 2008) of which protein-coding genes are an
abundant class. In contrast, CAGE method captures capped RNA
transcripts of both poly Aþ and poly A classes (Carninci, 2007).
This also may explain why some genes that appeared highly
expressed in brain in the RNA-Seq data set were not identiﬁed with
CAGE including mitochondrial and ribosomal genes because they
are uncapped and, therefore, not well covered by the CAGE
approach.
Recent studies show that ncRNAs regulate gene expression in
brain and play a role in the development and in the onset of
neurologic diseases (Schonrock et al., 2011). Most research has
focused on deciphering the functional role of lncRNAs and miRNAs,
but other classes of ncRNAs may also be important. We found that
more than 4.7% of the total RNA pool (and 24% of the ncRNA)
consisted of annotated pseudogenes. The contribution of this
ncRNA class to the transcriptome is currently unknown, with esti-
mates ranging from 5% (Frith et al., 2006), which is consistent with
our data, to 20% (Pink et al., 2011). Although the functional impact
of ncRNA classes was not assessed in this study, our ﬁndings
demonstrate that pseudogene expression is a pervasive feature of
the transcriptome in aged brain.
We found expression patterns consistent with aging, including
high expression of GPAFP (Starkey et al., 2012) and SPARCL1, which
are markers of gliosis, and high expression of genes involved in
protection against oxidative stress and amyloid aggregation. This
group includes CLU, the gene for clusterin, an extracellular chap-
erone that maintains stressed proteins in a soluble state, thereby
preventing their precipitation (Poon et al., 2002). Clusterin coloc-
alizes with amyloid plaques and neuroﬁbrillary tangles, and it has
been suggested that it protects neurons from aggregate-induced
damage (Yerbury et al., 2007). The ubiquitin-proteosome pathway
was overrepresented in the group of highly expressed genes. This
pathway has been shown to be downregulated in disorders such as
AD and PD (Dennissen et al., 2012), and this decrease correlates
with a failure of neurons to remove toxic protein aggregates. In thisregard, it is important to stress that despite some pathologic ﬁnd-
ings consistent with aging, none of the 7 donors used for this study
showed any overt AD or PD pathology (Braak tangle stages 3 and
Braak a-synuclein stage 0eIV; Supplementary Table 1). These
results suggest that increased expression of genes involved in the
ubiquitin-proteosome pathway and neuroprotection (e.g., CLU) may
help to protect against overt protein aggregation in aged healthy
individuals.
It has been recently shown that alternative promoter usage and
alternative splicing can explain differences in gene expression
across brain regions (Pal et al., 2011; Tollervey et al., 2011). Our data
support the role of alternative promoters in causing expression
differences between brain regions. We found that 81% of the DETCs
were putative alternative TSS of genes with a main promoter that
was similarly expressed in all the regions analyzed. This shows that
the major transcripts were more often uniformly expressed
whereas alternative transcripts were more likely to be region
speciﬁc. Alternative promoters can alter the expression of a main
transcript by competing for the cell’s transcription machinery
(Davuluri et al., 2008) or by antagonizing the effects of the main
transcript (Tschan et al., 2003). For example, we found a DETC in
M18 (Supplementary Table 5) mapping to the promoter region of
a short isoform of DMTF1, which has been shown to antagonize the
effects of the main DMTF1 transcript in myeloid lines (Tschan et al.,
2003). Whether the expression of the shorter isoform leads to the
same changes observed in other cells cannot be ascertained here,
but it suggests an interesting mechanism by which alternative
promoter usage might lead to differences in expression.
In our data, most of the ATCs that were differentially expressed
were located in noncanonical gene regions (Fig. 1a), particularly in
introns. Although there is evidence that CAGE tags can also mark
post-transcriptional events (Mercer et al., 2010), we provide several
lines of evidence indicating that a proportion of transcription is
initiated from noncanonical gene regions. First, we only included
CAGE clusters present in at least 2 biological replicas, which makes
it unlikely that a tag identiﬁed twice is the result of an artifact.
Second, we found that at least one-third of noncanonical TCs
overlapped with other signatures of promoter activity derived from
H3K4me3 histone marks (data not shown). In addition, we
conﬁrmed with RACE the existence of capped products for 4
putative alternative TSSs in the CNP, RTN4, NRG3, and AUTS2 genes
(Supplementary data, Results), whichmay represent novel isoforms
for those genes. Indeed, we conﬁrmed experimentally the presence
of an alternative TSS in the intronic region of AUTS2, which is
associated with a shorter transcript that was previously only in
silico predicted. Our results indicate that at least one-third of
alternative TSS map to intronic gene regions.
Several growth factor signaling pathways have been implicated
in the alterations that render neuronal cell populations susceptible
to neurodegeneration. Our data showed that the FGF, epidermal
growth factor (EGF), insulin growth factor (IGF), and platelet-
derived growth factor pathways were overrepresented in several
differentially expressed modules (Supplementary Fig. 5 and
Table 4a). Common to these pathways is the mitogen-activated
protein kinase (MAPK) cascade that has a broad range of effects on
cellular function including survival and differentiation (Thomas and
Huganir, 2004). The FGF signaling pathway was the most signiﬁ-
cantly overrepresented pathway in module M27, where a reduced
expression in hippocampus was observed. The hippocampal region
is a primary target of the neurodegenerative changes that lead to
cognitive impartment and AD. Several mechanisms have been
suggested to lead to hippocampal dysfunction, including decreased
neuronal plasticity and increased calcium toxicity. The FGF pathway
can inﬂuence neural plasticity through several mechanisms
including MAPK/ERK activation (Thomas and Huganir, 2004), and
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regions. These ﬁndings suggest that the FGF pathway could be an
important target for pharmacologic treatments to combat
neurodegeneration.
The caudate and putamen regions (striatum), which are
components of the cortical-subcortical circuits of motor functions,
are particularly susceptible to neurodegeneration in disorders such
as Huntington’s disease and PD (DeLong and Wichmann, 2007).
Interestingly, functional enrichment analysis based on several
DETCs showed that genes encoding components of the Wnt
signaling pathway and the mGluRI were signiﬁcantly over-
represented in the modules where coexpression in the striatal
regions was observed (M18; Table 2). Both Wnt signaling and
mGluRI have been implicated in the development or progression of
PD (Johnson et al., 2009; L’Episcopo et al., 2011). Moreover, mGluRI
modulates neurotransmission throughout the basal ganglia, and its
deregulation can contribute to neuronal damage (Johnson et al.,
2009). Our results suggest that in the absence of a clear genetic
risk, pathways other than those associated with classical mutations
are important determinants of the regional vulnerability in the
aging brain.
We investigated whether differences in expression could be
attributed to differential TF expression. We found that 7% of TFs
were differentially expressed, and many of these have been shown
to be involved in the neurodevelopment, which is unexpected given
that neurons are postmitotic cells. The TFBS analysis also showed an
overrepresentation binding sites for TFs involved in neuro-
development. There are few explanations for this ﬁnding including
a bias in the literature toward functional annotation of neuro-
developmental TFs. Another plausible explanation is that, as the
brain ages, these genes may become derepressed because of, for
example, damage in their promoter regions. Although we did not
ﬁnd decreased methylation in the group of DETFs, we found
decreased methylation in the promoter region of this group and
increased methylation in the 30 UTRs. Methylation marks at both
ends of transcriptional units could affect the expression of the
group of DETFs (Jones, 2012).
Our analysis of methylation indicated that most of the methyl-
ation signals in our samples mapped to gene bodies and outside
CpG islands. This is consistent with recent evidence that in brain
most methylation signals occur within gene bodies, most likely in
association with alternative promoters (Maunakea et al., 2010).
However, we did not ﬁnd an overall correlation between methyl-
ation and TC expression. Several factors could account for the lack
of correlation. For example, batch effects were evident in the CAGE
data set. In addition, only 9% of the methylated regions colocalized
with a TC, which means that most of the expression in our data
remained uninvestigated. The lack of overlap between the MPs and
the CAGE clusters could also be because of the fact that the arrays
we used to proﬁle methylation were biased toward annotated
promoters and CpG islands, whereas our CAGE clusters mapped to
a large extent to noncanonical regions. Last, as a result of the small
sample size, most of MPs were identiﬁed in less than 5 samples and
were removed from the statistical analyses. Despite this drawback,
we identiﬁed several gene-associated TCs that were affected by
methylation, some of which were already documented (Iwamoto
et al., 2011).
Our study is far from being comprehensive because of our
small sample size and the limited number of brain regions
analyzed. In addition, because of the diverse cellular composition
of the brain, one might argue that the expression we observed
is not exclusive to neuronal populations, although neurons and
glia cells represent most of the cellular pool in human brain.
A separate issue is that most of our bioinformatics analysis
used public databases, which are still incomplete. For example,many protein-coding genes that we found differentially expressed
could not be assigned to any functional pathway because of a lack
of annotation. Therefore, inferences about functional pathways
are based on a limited number of genes. Nonetheless, our data
set provides an important addition to existing data on spatial
expression patterns in brain.
In summary, our study shows that despite the absence of
neuropathologic hallmarks of neurodegenerative disease, genetic
signatures related to neurodegeneration were already present in
brain regions that are highly vulnerable to neurologic disorders. We
showed that differences in transcription initiation and hence gene
expression between brain regions are partly explained by alterna-
tive promoter usage and that speciﬁc signaling pathways are
affected by the differential patterns in gene expression that we
observed. Our data are a starting point to investigate regional
susceptibility to brain aging and neurodegeneration.
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